Astellas Pharma (OTCMKTS:ALPMY) Posts Quarterly Earnings Results

Astellas Pharma (OTCMKTS:ALPMY) posted its earnings results on Tuesday. The company reported $0.30 EPS for the quarter, Zacks reports. Astellas Pharma had a return on equity of 10.40% and a net margin of 3.26%.

Astellas Pharma Price Performance

Astellas Pharma stock opened at $9.52 on Tuesday. The company has a current ratio of 1.10, a quick ratio of 0.86 and a debt-to-equity ratio of 0.41. Astellas Pharma has a 12-month low of $9.05 and a 12-month high of $13.14. The firm has a market capitalization of $17.22 billion, a PE ratio of 45.31 and a beta of 0.34. The firm has a 50-day moving average price of $9.87 and a 200-day moving average price of $10.97.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.